Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
1(9%)
Results Posted
67%(6 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_1
4
36%
Ph phase_2
2
18%
Ph not_applicable
5
45%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
4(36.4%)
Phase 2Efficacy & side effects
2(18.2%)
N/ANon-phased studies
5(45.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(9)
Terminated(1)

Detailed Status

Completed9
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
90.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (36.4%)
Phase 22 (18.2%)
N/A5 (45.5%)

Trials by Status

terminated19%
active_not_recruiting19%
completed982%

Recent Activity

Clinical Trials (11)

Drug Details

Intervention Type
RADIATION
Total Trials
11